GFPT2 and cancer: In non-small cell lung cancer, KRAS/LKB1 co-mutant cancer cells showed high levels of hexosamine biosynthesis pathway (HBP) metabolites, higher flux through the HBP and elevated dependence on the HBP enzyme GFPT2.